keyword
https://read.qxmd.com/read/38423649/bbt-877-a-novel-autotaxin-inhibitor-abrogates-drug-resistance-in-epithelial-ovarian-cancer-stem-cells
#21
JOURNAL ARTICLE
Jun Se Kim, Min Joo Shin, Seo Yul Lee, Seong Min Choi, Kyung-Un Choi, Dong-Soo Suh, Dae Kyoung Kim, Jae Ho Kim
BACKGROUND/AIM: Cancer stem cells (CSCs) contribute significantly to the poor prognosis of patients with epithelial ovarian cancer (EOC) due to their roles in drug resistance and tumor metastasis. Autotaxin (ATX) plays a pivotal role in the maintenance of the CSC-like properties of EOC tumors. BBT-877 is a novel ATX inhibitor used in clinical treatment of idiopathic pulmonary fibrosis. However, the effects of BBT-877 on drug resistance and metastasis in ovarian CSCs remain unknown. In this study, we aimed to investigate the effects of BBT-877 on drug resistance and intraperitoneal metastasis of EOC...
March 2024: Anticancer Research
https://read.qxmd.com/read/38408192/dosage-optimization-for-reducing-tumor-burden-using-a-phenotype-structured-population-model-with-a-drug-resistance-continuum
#22
JOURNAL ARTICLE
Lifeng Han, Osman N Yogurtcu, Marisabel Rodriguez Messan, Wencel Valega-Mackenzie, Ujwani Nukala, Hong Yang
Drug resistance is a significant obstacle to effective cancer treatment. To gain insights into how drug resistance develops, we adopted a concept called fitness landscape and employed a phenotype-structured population model by fitting to a set of experimental data on a drug used for ovarian cancer, Olaparib Our modeling approach allowed us to understand how a drug affects the fitness landscape and track the evolution of a population of cancer cells structured with a spectrum of drug resistance. We also incorporated pharmacokinetic (PK) modeling to identify the optimal dosages of the drug that could lead to long-term tumor reduction...
February 26, 2024: Mathematical Medicine and Biology: a Journal of the IMA
https://read.qxmd.com/read/38407966/a-novel-synthesized-cyclohexane-hydroxytyrosol-derivative-suppresses-ovarian-cancer-cell-growth-through-inducing-ros-and-blocking-autophagic-flux
#23
JOURNAL ARTICLE
Guanfei Zhang, Min Wang, Yilin Gao, Aikaterini-Christina Komianou, Eleftheria A Georgiou, Yan Wang, Yezi Zheng, Jiankang Liu, Ioannis K Kostakis, Lin Zhao
AIMS: Drug resistance in ovarian cancer (OC) cells often leads to recurrence, metastasis, and high mortality rates among OC patients. Hydroxytyrosol (HT) has been reported to inhibit the proliferation of ovarian and other types of cancer cells. Here we synthesized a novel cyclohexane-hydroxytyrosol derivative (Chx-HT) for enhanced anticaner efficacy. We examined the growth-suppressing effect of Chx-HT on OC cells in vitro and in xenograft mouse model and investigated the underlying mechanism...
February 26, 2024: Antioxidants & Redox Signaling
https://read.qxmd.com/read/38401050/paraptotic-cell-death-as-an-unprecedented-mode-of-action-observed-for-new-bipyridine-silver-i-compounds-bearing-phosphane-coligands
#24
JOURNAL ARTICLE
Ricardo G Teixeira, Alessia Stefanelli, Adhan Pilon, Rebecca Warmers, Xavier Fontrodona, Isabel Romero, Paulo J Costa, Maria J Villa de Brito, Xenia Hudec, Christine Pirker, Sebastian Türck, Alexandra M M Antunes, Christian R Kowol, Ingo Ott, Anamaria Brozovic, Andy Sombke, Margret Eckhard, Ana Isabel Tomaz, Petra Heffeter, Andreia Valente
In this work, we investigated the anticancer activity of several novel silver(I) 2,2'-bipyridine complexes containing either triphenylphosphane (PPh3 ) or 1,2-bis(diphenylphosphino)ethane (dppe) ligands. All compounds were characterized by diverse analytical methods including ESI-MS spectrometry; NMR, UV-vis, and FTIR spectroscopies; and elemental analysis. Moreover, several compounds were also studied by X-ray single-crystal diffraction. Subsequently, the compounds were investigated for their anticancer activity against drug-resistant and -sensitive cancer cells...
February 24, 2024: Journal of Medicinal Chemistry
https://read.qxmd.com/read/38398161/recent-therapeutic-advances-in-gynecologic-oncology-a-review
#25
REVIEW
Elise M Wilson, Ramez N Eskander, Pratibha S Binder
Gynecologic malignancies have high incidence rates both nationally and internationally, and cervical, endometrial, and ovarian cancers account for high mortality rates worldwide. Significant research is ongoing to develop targeted therapies to address unmet needs in the field and improve patient outcomes. As tumors mutate and progress through traditional lines of treatment, new therapies must be developed to overcome resistance and target cancer-specific receptors and mutations. Recent advances in the development of immunotherapy and antibody-drug conjugates have resulted in compelling and clinically meaningful results in cervical, endometrial, and ovarian cancers...
February 13, 2024: Cancers
https://read.qxmd.com/read/38396800/developing-folate-conjugated-mir-34a-therapeutic-for-prostate-cancer-challenges-and-promises
#26
JOURNAL ARTICLE
Wen Jess Li, Yunfei Wang, Xiaozhuo Liu, Shan Wu, Moyi Wang, Steven G Turowski, Joseph A Spernyak, Amanda Tracz, Ahmed M Abdelaal, Kasireddy Sudarshan, Igor Puzanov, Gurkamal Chatta, Andrea L Kasinski, Dean G Tang
Prostate cancer (PCa) remains a common cancer with high mortality in men due to its heterogeneity and the emergence of drug resistance. A critical factor contributing to its lethality is the presence of prostate cancer stem cells (PCSCs), which can self-renew, long-term propagate tumors, and mediate treatment resistance. MicroRNA-34a (miR-34a) has shown promise as an anti-PCSC therapeutic by targeting critical molecules involved in cancer stem cell (CSC) survival and functions. Despite extensive efforts, the development of miR-34a therapeutics still faces challenges, including non-specific delivery and delivery-associated toxicity...
February 9, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38394731/lycorine-and-homolycorine-derivatives-for-chemo-sensitizing-resistant-human-ovarian-adenocarcinoma-cells
#27
JOURNAL ARTICLE
Shirley A R Sancha, Simona Dobiasová, Tomáš Nejedlý, Ondřej Strnad, Jitka Viktorová, Maria-José U Ferreira
BACKGROUND: Multidrug resistance is the major obstacle to cancer chemotherapy. Modulation of P-glycoprotein and drug combination approaches have been considered important strategies to overcome drug resistance. PURPOSE: Aiming at generating a small library of Amaryllidaceae-type alkaloids to overcome drug resistance, two major alkaloids, isolated from Pancratium maritimum, lycorine (1), and 2α-10bα-dihydroxy-9-O-demethylhomolycorine (2), were derivatized, giving rise to nineteen derivatives (3 - 21)...
February 16, 2024: Phytomedicine
https://read.qxmd.com/read/38383600/meiotic-protein-sycp2-confers-resistance-to-dna-damaging-agents-through-r-loop-mediated-dna-repair
#28
JOURNAL ARTICLE
Yumin Wang, Boya Gao, Luyuan Zhang, Xudong Wang, Xiaolan Zhu, Haibo Yang, Fengqi Zhang, Xueping Zhu, Badi Zhou, Sean Yao, Aiko Nagayama, Sanghoon Lee, Jian Ouyang, Siang-Boon Koh, Eric L Eisenhauer, Dominique Zarrella, Kate Lu, Bo R Rueda, Lee Zou, Xiaofeng A Su, Oladapo Yeku, Leif W Ellisen, Xiao-Song Wang, Li Lan
Drugs targeting the DNA damage response (DDR) are widely used in cancer therapy, but resistance to these drugs remains a major clinical challenge. Here, we show that SYCP2, a meiotic protein in the synaptonemal complex, is aberrantly and commonly expressed in breast and ovarian cancers and associated with broad resistance to DDR drugs. Mechanistically, SYCP2 enhances the repair of DNA double-strand breaks (DSBs) through transcription-coupled homologous recombination (TC-HR). SYCP2 promotes R-loop formation at DSBs and facilitates RAD51 recruitment independently of BRCA1...
February 21, 2024: Nature Communications
https://read.qxmd.com/read/38383406/zswim4-inhibition-improves-chemosensitivity-in-epithelial-ovarian-cancer-cells-by-suppressing-intracellular-glycine-biosynthesis
#29
JOURNAL ARTICLE
Kunxiang Gong, Yinger Huang, Yanqin Zheng, Wenbo Hao, Kun Shi
BACKGROUND: Zinc finger SWIM-type containing 4 (ZSWIM4) induces drug resistance in breast cancer cells. However, its role in epithelial ovarian cancer (EOC) remains unknown. In this study, we aimed to investigate the clinical significance of ZSWIM4 expression in EOC and develop new clinical therapeutic strategies for EOC. METHODS: ZSWIM4 expression in control and EOC tumor tissues was examined using immunohistochemistry. Lentiviral transduction, Cell Counting Kit-8 assay, tumorsphere formation assay, flow cytometry, western blotting, and animal xenograft model were used to assess the role of ZSWIM4 in chemotherapy...
February 21, 2024: Journal of Translational Medicine
https://read.qxmd.com/read/38382330/in-ovarian-cancer-maraviroc-potentiates-the-antitumoral-activity-and-further-inhibits-the-formation-of-a-tumor-promoting-microenvironment-by-trabectedin
#30
JOURNAL ARTICLE
Naike Casagrande, Cinzia Borghese, Giuseppe Corona, Donatella Aldinucci
Ovarian cancer (OC) is the fifth most frequent cause of cancer-related death in women. Chemotherapy agent trabectedin, affecting cancer cells and tumor microenvironment, has been approved for the treatment of relapsed platinum-sensitive OC patients. CCR5-antagonist maraviroc inhibits tumor growth, metastasis, and enhances the antitumoral activity of DNA-damaging drugs. Here, we found that OC cells expressed CCR5 receptor but did not secret CCR5-ligands. Maraviroc treatment did not affect OC cell viability, but strongly potentiated the antiproliferative activity, apoptosis induction, cell cycle blockage, DNA damage, and ROS formation by trabectedin...
February 20, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38374055/structural-basis-for-antibody-recognition-of-the-proximal-muc16-ectodomain
#31
JOURNAL ARTICLE
Kwangkook Lee, Kay Perry, Mengyao Xu, Irva Veillard, Raj Kumar, Thapi Dharma Rao, Bo R Rueda, David R Spriggs, Oladapo O Yeku
BACKGROUND: Mucin 16 (MUC16) overexpression is linked with cancer progression, metastasis, and therapy resistance in high grade serous ovarian cancer and other malignancies. The cleavage of MUC16 forms independent bimodular fragments, the shed tandem repeat sequence which circulates as a protein bearing the ovarian cancer biomarker (CA125) and a proximal membrane-bound component which is critical in MUC16 oncogenic behavior. A humanized, high affinity antibody targeting the proximal ectodomain represents a potential therapeutic agent against MUC16 with lower antigenic potential and restricted human tissue expression...
February 19, 2024: Journal of Ovarian Research
https://read.qxmd.com/read/38373690/sting-inhibitors-sensitize-platinum-chemotherapy-in-ovarian-cancer-by-inhibiting-the-cgas-sting-pathway-in-cancer-associated-fibroblasts-cafs
#32
JOURNAL ARTICLE
Jiale Liu, Chenmian Liu, Yana Ma, Xiyu Pan, Ran Chu, Shu Yao, Junyu Chen, Chang Liu, Zhongshao Chen, Chenchen Sheng, Kai Zhang, Ying Xue, Helgi B Schiöth, Beihua Kong, Qing Zhang, Kun Song
Chemotherapy resistance in ovarian cancer hampers cure rates, with cancer-associated fibroblasts (CAFs) playing a pivotal role. Despite their known impact on cancer progression and chemotherapy resistance, the specific mechanism by which CAFs regulate the tumor inflammatory environment remains unclear. This study reveals that cisplatin facilitates DNA transfer from ovarian cancer cells to CAFs, activating the CGAS-STING-IFNB1 pathway in CAFs and promoting IFNB1 release. Consequently, this reinforces cancer cell resistance to platinum drugs...
February 17, 2024: Cancer Letters
https://read.qxmd.com/read/38372034/cost-effectiveness-and-drug-wastage-of-bevacizumab-biosimilar-with-or-without-chemotherapy-for-platinum-resistant-recurrent-ovarian-cancer
#33
JOURNAL ARTICLE
Shih Ping Lai, Shyh-Yau Wang, Agnes Lf Chan, John Hang Leung, Hei-Tung Yip
INTRODUCTION: The cost-effectiveness of adding bevacizumab biosimilar with or without chemotherapy (CT) and drug wastage in treating platinum-resistant recurrent ovarian cancer (PRrOC) was assessed. METHODS: A three-state partitioned-survival model to compare the clinical and economic outcomes in the treatment of patients with PRrOC from a Taiwan healthcare prospective, extrapolated to two years based on data obtained from the JGOG3023 clinical trial. The primary outcomes of the model were incremental cost-effectiveness ratios (ICERs)...
February 19, 2024: Expert Review of Pharmacoeconomics & Outcomes Research
https://read.qxmd.com/read/38365611/upregulation-of-cald1-predicted-a-poor-prognosis-for-platinum-treated-ovarian-cancer-and-revealed-it-as-a-potential-therapeutic-resistance-target
#34
JOURNAL ARTICLE
Wei Li, Limei Huang, Nana Qi, Qinle Zhang, Zailong Qin
BACKGROUND: Ovarian cancer (OC) has the worst prognosis among gynecological malignancies, most of which are found to be in advanced stage. Cell reduction surgery based on platinum-based chemotherapy is the current standard of treatment for OC, but patients are prone to relapse and develop drug resistance. The objective of this study was to identify a specific molecular target responsible for platinum chemotherapy resistance in OC. RESULTS: We screened the protein-coding gene Caldesmon (CALD1), expressed in cisplatin-resistant OC cells in vitro...
February 16, 2024: BMC Genomics
https://read.qxmd.com/read/38357948/prediction-model-for-therapeutic-responses-in-ovarian-cancer-patients-using-paclitaxel-resistant-immune-related-lncrnas
#35
JOURNAL ARTICLE
Xin Li, Huiqiang Liu, Fanchen Wang, Jia Yuan, Wencai Guan, Guoxiong Xu
BACKGROUND: Ovarian cancer (OC) is the deadliest malignant tumor in women with a poor prognosis due to drug resistance and lack of prediction tools for therapeutic responses to anti- cancer drugs. OBJECTIVE: The objective of this study was to launch a prediction model for therapeutic responses in OC patients. METHODS: The RNA-seq technique was used to identify differentially expressed paclitaxel (PTX)- resistant lncRNAs (DE-lncRNAs). The Cancer Genome Atlas (TCGA)-OV and ImmPort database were used to obtain immune-related lncRNAs (ir-lncRNAs)...
February 14, 2024: Current Medicinal Chemistry
https://read.qxmd.com/read/38356723/cd206-modulates-the-role-of-m2-macrophages-in-the-origin-of-metastatic-tumors
#36
JOURNAL ARTICLE
Hui Li, Ying-Qi Miao, Li-Ping Suo, Xi Wang, Yi-Qing Mao, Xue-Hui Zhang, Na Zhou, Jun-Rui Tian, Xiu-Yan Yu, Tong-Xia Wang, Yan Gao, Hong-Yan Guo, Zheng Zhang, Dian-Sheng Ma, Hong-Xia Wu, Yan-Wei Cui, Xi-Liang Zhang, Xiao-Chun Chi, Yu-Chi Li, David M Irwin, Gang Niu, Huan-Ran Tan
Tumor metastasis is a key factor affecting the life of patients with malignant tumors. For the past hundred years, scientists have focused on how to kill cancer cells and inhibit their metastasis in vivo , but few breakthroughs have been made. Here we hypothesized a novel mode for cancer metastasis. We show that the phagocytosis of apoptotic tumor cells by macrophages leads to their polarization into the M2 phenotype, and that the expression of stem cell related as well as drug resistance related genes was induced...
2024: Journal of Cancer
https://read.qxmd.com/read/38356716/gene-expression-profile-analysis-of-the-molecular-mechanism-of-hoxd10-regulation-of-epithelial-ovarian-cancer-cells
#37
JOURNAL ARTICLE
Chia-Yi Hsu, Ching-Chou Tsai, Hsiao-Yun Lin, Hsiang-Ling Chen, Yu-Che Ou, Ping-Hsuan Chiang, Jau-Ling Suen, Eing-Mei Tsai
Epithelial ovarian cancer (EOC) is the most common type of ovarian cancer. Although studies have reported that downregulation of HOXD10 expression may contribute to the migration and invasion abilities in EOC, much about its regulation remains to be fully elucidated. The present study aimed to identify different gene expression profiles associated with HOXD10 overexpression in EOC cells. The present study confirmed that HOXD10 overexpression effectively inhibited the proliferation and motility of the TOV21G and TOV112D cells...
2024: Journal of Cancer
https://read.qxmd.com/read/38347608/from-clinical-management-to-personalized-medicine-novel-therapeutic-approaches-for-ovarian-clear-cell-cancer
#38
REVIEW
Zesi Liu, Chunli Jing, Fandou Kong
Ovarian clear-cell cancer is a rare subtype of epithelial ovarian cancer with unique clinical and biological features. Despite optimal cytoreductive surgery and platinum-based chemotherapy being the standard of care, most patients experience drug resistance and a poor prognosis. Therefore, novel therapeutic approaches have been developed, including immune checkpoint blockade, angiogenesis-targeted therapy, ARID1A synthetic lethal interactions, targeting hepatocyte nuclear factor 1β, and ferroptosis. Refining predictive biomarkers can lead to more personalized medicine, identifying patients who would benefit from chemotherapy, targeted therapy, or immunotherapy...
February 12, 2024: Journal of Ovarian Research
https://read.qxmd.com/read/38345575/machine-learning-constructs-a-t-cell-related-signature-for-predicting-prognosis-and-drug-sensitivity-in-ovarian-cancer
#39
JOURNAL ARTICLE
Yunzheng Zhang, Lipeng Pei
BACKGROUND: The leading cause of death related to gynecologic cancer is ovarian cancer, which typically has a poor prognosis. T cells are referred to as key mediators of immunosurveillance and tumor eradication, and unbalanced regulation or lack of T cells in tumors result in immunotherapy resistance. METHODS: The identification of T cell related markers depended on single-cell RNA-seq analysis. Using data from multiple datasets, including TCGA, GSE14764, GSE26193, GSE26712, and GSE140082, we constructed a prognostic signature called TRS (T cell-related signature) using 10 different machine learning algorithms...
February 9, 2024: Aging
https://read.qxmd.com/read/38342698/personalized-versus-precision-nanomedicine-for-treatment-of-ovarian-cancer
#40
JOURNAL ARTICLE
Olga B Garbuzenko, Justin Sapiezynski, Eugenia Girda, Lorna Rodriguez-Rodriguez, Tamara Minko
The response to treatment is substantially varied between individual patients with ovarian cancer. However, chemotherapy treatment plans rarely pay sufficient attention to the mentioned factors. Instead, standardized treatment protocols are usually employed for most ovarian cancer patients. Variations in an individual's sensitivity to drugs significantly limit the effectiveness of treatment in some patients and lead to severe toxicities in others. In the present investigation, a nanotechnology-based approach for personalized treatment of ovarian carcinoma (the most lethal type of gynecological cancer) constructed on the individual genetic profile of the patient's tumor is developed and validated...
February 11, 2024: Small
keyword
keyword
164841
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.